Precision Drug Olaparib May Be Effective Without Hormone Therapy for Some Men With Biochemically Recurrent Prostate Cancer
August 22, 2024
August 22, 2024
BALTIMORE, Maryland, Aug. 22 (TNSres) -- Johns Hopkins Medicine issued the following news release:
The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a phase II clinical trial of 51 patients conducted at the Johns Hopkins Kimmel Cancer Center and three other sites.
The study was done of men experiencing signs of . . .
The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a phase II clinical trial of 51 patients conducted at the Johns Hopkins Kimmel Cancer Center and three other sites.
The study was done of men experiencing signs of . . .